{
    "clinical_study": {
        "@rank": "35141", 
        "acronym": "COBALT", 
        "arm_group": {
            "arm_group_label": "OZURDEX\u00ae", 
            "arm_group_type": "Experimental", 
            "description": "OZURDEX\u00ae (700 \u00b5g dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of OZURDEX\u00ae (700 \u00b5g dexamethasone implant)\n      in patients with macular edema associated with branch retinal vein occlusion."
        }, 
        "brief_title": "A Safety and Efficacy Study of OZURDEX\u00ae in Macular Edema Associated With Branch Retinal Vein Occlusion", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Macular Edema", 
            "Retinal Vein Occlusion"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of macular edema\n\n          -  Best corrected visual acuity of approximately 20/400 to 20/40 in the study eye\n\n        Exclusion Criteria:\n\n          -  Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or\n             extensive dermal) within 1 month\n\n          -  Intraocular surgery, including cataract surgery, and/or laser surgery of any type\n             within 3 months\n\n          -  Any active ocular infection in either eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903720", 
            "org_study_id": "APMA-OZU-01-01"
        }, 
        "intervention": {
            "arm_group_label": "OZURDEX\u00ae", 
            "description": "OZURDEX\u00ae (700 \u00b5g dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.", 
            "intervention_name": "dexamethasone implant", 
            "intervention_type": "Drug", 
            "other_name": "OZURDEX\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Best Corrected Visual Acuity (BCVA)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Month 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903720"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Central Retinal Thickness (CRT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6"
            }, 
            {
                "measure": "Change from Baseline in BCVA", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12"
            }, 
            {
                "measure": "Change from Baseline in CRT", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 12"
            }, 
            {
                "measure": "Percentage of Subjects with a Change from Baseline of 15 or More Letters in BCVA", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Months"
            }, 
            {
                "measure": "Percentage of Subjects Receiving a Second Injection", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Percentage of Subjects Receiving a Third Injection", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Time to Second Injection", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Time to Third Injection", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Number of Laser Treatments", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}